Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers
Caterina Longo, Alexis Patanarut, Tony George, Barney Bishop, Weidong Zhou, Claudia Fredolini, Mark M Ross, Virginia Espina, Giovanni Pellacani, Emanuel F Petricoin 3rd, Lance A Liotta, Alessandra Luchini, Caterina Longo, Alexis Patanarut, Tony George, Barney Bishop, Weidong Zhou, Claudia Fredolini, Mark M Ross, Virginia Espina, Giovanni Pellacani, Emanuel F Petricoin 3rd, Lance A Liotta, Alessandra Luchini
Abstract
Background: The blood proteome is thought to represent a rich source of biomarkers for early stage disease detection. Nevertheless, three major challenges have hindered biomarker discovery: a) candidate biomarkers exist at extremely low concentrations in blood; b) high abundance resident proteins such as albumin mask the rare biomarkers; c) biomarkers are rapidly degraded by endogenous and exogenous proteinases.
Methodology and principal findings: Hydrogel nanoparticles created with a N-isopropylacrylamide based core (365 nm)-shell (167 nm) and functionalized with a charged based bait (acrylic acid) were studied as a technology for addressing all these biomarker discovery problems, in one step, in solution. These harvesting core-shell nanoparticles are designed to simultaneously conduct size exclusion and affinity chromatography in solution. Platelet derived growth factor (PDGF), a clinically relevant, highly labile, and very low abundance biomarker, was chosen as a model. PDGF, spiked in human serum, was completely sequestered from its carrier protein albumin, concentrated, and fully preserved, within minutes by the particles. Particle sequestered PDGF was fully protected from exogenously added tryptic degradation. When the nanoparticles were added to a 1 mL dilute solution of PDGF at non detectable levels (less than 20 picograms per mL) the concentration of the PDGF released from the polymeric matrix of the particles increased within the detection range of ELISA and mass spectrometry. Beyond PDGF, the sequestration and protection from degradation for a series of additional very low abundance and very labile cytokines were verified.
Conclusions and significance: We envision the application of harvesting core-shell nanoparticles to whole blood for concentration and immediate preservation of low abundance and labile analytes at the time of venipuncture.
Conflict of interest statement
Competing Interests: The technology described herein is licensed (patent pending) to the authors institutions (George Mason University, USA and Istituto Superiore di Sanita', Italy). Under faculty guidelines the University authors can received a share of the patent royalties owned by the university.
Figures
References
- Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature. 2003;425:905.
- Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845–867.
- Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572–577.
- Merrell K, Southwick K, Graves SW, Esplin MS, Lewis NE, et al. Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. J Biomol Tech. 2004;15:238–248.
- Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer. 2006;6:961–967.
- Lopez MF, Mikulskis A, Kuzdzal S, Bennett DA, Kelly J, et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem. 2005;51:1946–1954.
- Zhou M, Lucas DA, Chan KC, Issaq HJ, Petricoin EF, 3rd, et al. An investigation into the human serum “interactome”. Electrophoresis. 2004;25:1289–1298.
- Ayache S, Panelli M, Marincola FM, Stroncek DF. Effects of storage time and exogenous protease inhibitors on plasma protein levels. Am J Clin Pathol. 2006;126:174–184.
- Luchini A, Geho DH, Bishop B, Tran D, Xia C, et al. Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett. 2008;8:350–361.
- Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev. 2002;54:3–12.
- Drury JL, Mooney DJ. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials. 2003;24:4337–4351.
- Bowen-Pope DF, Malpass TW, Foster DM, Ross R. Platelet-derived growth factor in vivo: levels, activity, and rate of clearance. Blood. 1984;64:458–469.
- Hennink WE, van Nostrum CF. Novel crosslinking methods to design hydrogels. Adv Drug Deliv Rev. 2002;54:13–36.
- Pelton R. Temperature-sensitive aqueous microgels. Adv Colloid Interface Sci. 2000;85:1–33.
- Nayak S, Gan D, Serpe MJ, Lyon LA. Hollow thermoresponsive microgels. Small. 2005;1:416–421.
- Fortina P, Kricka LJ, Surrey S, Grodzinski P. Nanobiotechnology: the promise and reality of new approaches to molecular recognition. Trends Biotechnol. 2005;23:168–173.
- Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19:311–330.
- Sakamoto JH, Smith BR, Xie B, Rokhlin SI, Lee SC, et al. The molecular analysis of breast cancer utilizing targeted nanoparticle based ultrasound contrast agents. Technol Cancer Res Treat. 2005;4:627–636.
- Li X, Ponten A, Aase K, Karlsson L, Abramsson A, et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol. 2000;2:302–309.
- Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004;15:197–204.
- Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710.
- Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet. 2002;11:1391–1397.
- Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol. 2003;36:49–59.
- Board R, Jayson GC. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat. 2005;8:75–83.
- Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65.
- McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866–873.
- Mathew P, Thall PF, Jones D, Perez C, Bucana C, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol. 2004;22:3323–3329.
- Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer. 2008;112:2119–2129.
- Kagami S, Kakinuma T, Saeki H, Tsunemi Y, Fujita H, et al. Increased serum CCL28 levels in patients with atopic dermatitis, psoriasis vulgaris and bullous pemphigoid. J Invest Dermatol. 2005;124:1088–1090.
- Jahnz-Rozyk K, Targowski T, Glodzinska-Wyszogrodzka E, Plusa T. Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis. Allergy. 2003;58:595–601.
- Robak E, Kulczycka L, Sysa-Jedrzejowska A, Wierzbowska A, Robak T. Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw. 2007;18:181–187.
- Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines–CXC and CC chemokines. Adv Immunol. 1994;55:97–179.
- Frederick MJ, Clayman GL. Chemokines in cancer. Expert Rev Mol Med. 2001;3:1–18.
- Braude EA, Nachod FC. Determination of Organic Structures by Physical Methods. New York: Academic Press; 1955.
- Denizli A, Piskin E. Dye-ligand affinity systems. J Biochem Biophys Methods. 2001;49:391–416.
- Sereikaite J, Bumelis VA. Examination of dye-protein interaction by gel-permeation chromatography. Biomed Chromatogr. 2006;20:195–199.
- Fredolini C, Meani F, Reeder KA, Rucker S, Patanarut A, et al. Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles. Nano Res. 2008;1:502–518.
- Uekama K, Hirayama F, Arima H. Recent Aspect of Cyclodextrin-Based Drug Delivery System. J Inclusion Phenom Macrocyclic Chem. 2006;56:3–8.
- Jin S, Lee Y, Kang H. Methyl-β-cyclodextrin, a specific cholesterol-binding agent, inhibits melanogenesis in human melanocytes through activation of ERK. Arch Dermatol Res. 8:451–454.
- Cai W, Yao X, Shao X, Pan Z. Bimodal Complexations of Steroids with Cyclodextrins by a Flexible Docking Algorithm. J Inclusion Phenom Macrocyclic Chem. 2005;51:41–51.
- Borst C, Holzgrabe U. Enantioseparation of dopa and related compounds by cyclodextrin-modified microemulsion electrokinetic chromatography. J Chromatogr A 2008
- Dodziuk H. Cyclodextrins and Their Complexes: Chemistry, Analytical Methods, Applications. Hoboken: Wiley-VCH; 2006.
- Elmas B, Onur M, Şenel S, Tuncel A. Temperature controlled RNA isolation by N-isopropylacrylamide-vinylphenyl boronic acid copolymer latex. Colloid Polym Sci. 2002;280:1137–1146.
- Kataoka K, Miyazaki H, Okano T, Sakurai Y. Sensitive Glucose-Induced Change of the Lower Critical Solution Temperature of Poly[N,N-(dimethylacrylamide)-co-3-(acrylamido)-phenylboronic acid] in Physiological Saline. Macromolecules. 1994;27:1061–1062.
- Lorand JP, Edwards JO. Polyol Complexes and Structure of the Benzeneboronate Ion. J Org Chem. 1959;24:769–774.
- Mader HS, Wolfbeis OS. Boronic acid based probes for microdetermination of saccharides and glycosylated biomolecules. Mikrochim Acta. 2008;162:1–34.
- Yamauchi A, Suzuki I, Hayashita T. Saccharide recognition by Boronic Acid Fluorophore/Cyclodextrin Complexes in Water. In: Geddes CDL, Joseph R, editors. Glucose Sensing, Topics in Fluorescence Spectroscopy. Springer; 2006. pp. 237–258.
- Zhang Y, Gao X, Hardcastle K, Wang B. Water-soluble fluorescent boronic acid compounds for saccharide sensing: substituent effects on their fluorescence properties. Chemistry. 2006;12:1377–1384.
- Jones CD, Lyon LA. Synthesis and Characterization of Multiresponsive Core-Shell Microgels. Macromolecules. 2000;33:8301–8306.
- Couvreur P, Reddy LH, Mangenot S, Poupaert JH, Desmaele D, et al. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small. 2008;4:247–253.
- Cho EC, Kim JW, Fernandez-Nieves A, Weitz DA. Highly responsive hydrogel scaffolds formed by three-dimensional organization of microgel nanoparticles. Nano Lett. 2008;8:168–172.
- Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clinical cancer research. 2008;14:2378–2386.
- Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ. 2007;177:361–368.
- Pecora R. Dynamic Light Scattering: Applications of Photo Correlation Spectroscopy. Springer; 1985. p. 436.
Source: PubMed